# Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).

> **NCT05010876** · PHASE2 · COMPLETED · sponsor: **GCS Ramsay Santé pour l'Enseignement et la Recherche** · enrollment: 44 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** C1 Inhibitor Human
- **DRUG:** Icatibant Injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05010876
- **Lead sponsor:** GCS Ramsay Santé pour l'Enseignement et la Recherche
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-04
- **Primary completion:** 2021-06-13
- **Final completion:** 2021-06-21
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05010876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05010876, "Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05010876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*